Pulmonary Hypertension Clinical Trials

Find Pulmonary Hypertension Clinical Trials Near You

Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year. Conditioning and maintenance regimens carry a risk of both short- and long-term cardiotoxicity, leading to serious cardiovascular events including acute coronary syndrome (ACS), cardiac dysfunction, arrhythmias, pulmonary hypertension, and pericardial effusion. The pathophysiology of cardiotoxicity in HSCT patients remains poorly understood. It is therefore crucial to investigate underlying mechanisms and identify predictive factors of cardiotoxicity in order to provide appropriate cardiological follow-up and management. Current European Society of Cardiology guidelines recommend routine monitoring of HSCT patients with echocardiography and cardiac biomarkers (NT-proBNP, troponin), although these recommendations are based on small-scale studies. The cardiodepressor factor DPP3 has shown promising results in cardio-oncology, with a causal role in anthracycline-induced cardiac dysfunction. Its role in HSCT-related cardiotoxicity requires further evaluation. This multicenter study of HSCT recipients will be a valuable resource, enabling a better understanding of the pathophysiology of cardiotoxicity and prognosis. It will highlight imaging (echocardiography, calcium score, supra-aortic Doppler), electrocardiographic, and biological markers (including DPP3) associated with prognosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 15
Healthy Volunteers: f
View:

• Age ≥ 15 years

• Informed about the study and without objection to participation (or with consent from legal guardians)

• Undergoing allogeneic HSCT

Locations
Other Locations
France
Saint Louis Hospital
RECRUITING
Paris
Contact Information
Primary
Trecy Dr Gonçalves, Dr
trecy.goncalves@aphp.fr
+33142499162
Time Frame
Start Date: 2025-12-25
Estimated Completion Date: 2028-12-25
Participants
Target number of participants: 400
Treatments
Cohort of consecutive HSCT patients.
Sponsors
Collaborators: INSERM U1086 Cancers et Préventions, Fédération Française de Cardiologie, INSERM UMR-S 942 MASCOT
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov